{
  "run_id": "30f76f18-baff-4404-b895-2ced5d1b255e",
  "prompt_variant_id": "370d096a-9ab4-4952-8b74-7133a53e3ff1",
  "api_config_name": "model_deepseek_chat",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T13:13:31.801561",
  "end_time": "2025-09-01T13:15:17.362086",
  "duration_ms": 105557.33919143677,
  "success": true,
  "error_message": "",
  "entities_extracted": 24,
  "entities_mapped": 21,
  "extraction_completeness": 1.5,
  "mapping_accuracy": 0.5833333333333334,
  "precision": 0.5769230769230769,
  "recall": 0.9375,
  "f1_score": 0.7142857142857143,
  "compliance_score": 1.0,
  "token_usage": 5970,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 0,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 25,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Histologically confirmed HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "30-85",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "55-68",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "87-118",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "107-117",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "120-146",
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": "adequate",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "148-170",
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "190-230",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "210-233",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "235-257",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "259-268",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "breastfeeding",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "272-284",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 20,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": 60,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": 75,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 95,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 110,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-32",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "33-45",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "40-52",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "53-63",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "64-76",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "Mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct mapping to cancer condition with HER2 biomarker status",
      "id": "385e7119-61b3-4314-8d85-de8e21b13d13",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "ccf96a37-5578-480f-9c60-78e8b3c60028",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "bb143bed-3349-4ac2-a9e2-326db26f2674",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "Complete cancer diagnosis with biomarker and metastatic status",
      "id": "e629608e-bbb6-4ec2-a241-89469d2fab2c",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "fd69028b-2f91-4f15-a41e-43f72d215f79",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Active disease",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Measurable disease implies active cancer status per RECIST criteria",
      "id": "c2de8178-852e-4d00-aef2-595c6d96c198",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "Mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "RECIST 1.1 assessment",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "RECIST 1.1 is a standardized procedure for tumor response assessment",
      "id": "56ee93d8-7bac-45c5-8a1f-cf3a718eb3dc",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "Direct mapping to ECOG performance status scale",
      "id": "ac6d99c8-ce21-4148-ac76-71e7cfc389f5",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "HER2-targeted therapy medication with exclusion status",
      "id": "3d6e37ba-3b38-444d-bb54-269df2520afb",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Specific HER2-targeted therapy medication",
      "id": "eb3554ef-4d0d-40f3-9939-10132e1a72f6",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Brain metastases",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Metastatic cancer condition with active status (exclusion)",
      "id": "98a2e381-8b04-48a7-b0c9-437b371b086a",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "General class of HER2-targeted medications",
      "id": "48d0fff0-5252-4df0-9b94-b028d67f8c87",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "db6c119c-9297-4ac7-a742-759fdea004f4",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Metastatic cancer condition",
      "id": "6106bf25-8047-4add-9d3e-dd19ce8ba05a",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Progression",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 18",
      "mapping_rationale": "Disease progression status indicating treatment failure",
      "id": "9a8e151d-1303-45d7-84ad-e8255c1c202c",
      "llm_source_text_fragment": "Entity index 18",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab-based therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 19",
      "mapping_rationale": "Prior HER2-targeted therapy regimen",
      "id": "9e00b803-6df9-4c1a-aa2c-74d7df0a40bd",
      "llm_source_text_fragment": "Entity index 19",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 20",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "f1309261-4ea8-44b9-a05e-b578e1606ed3",
      "llm_source_text_fragment": "Entity index 20",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 21",
      "mapping_rationale": "Primary cancer diagnosis",
      "id": "866af81f-399d-4389-b25e-53444d1463f3",
      "llm_source_text_fragment": "Entity index 21",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 22",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "deef500f-8891-4309-82e8-4a761d96cb8c",
      "llm_source_text_fragment": "Entity index 22",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 23",
      "mapping_rationale": "Metastatic cancer condition",
      "id": "6555e6a3-57db-4dcd-a1ca-bf768606b5f2",
      "llm_source_text_fragment": "Entity index 23",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 24",
      "mapping_rationale": "Primary cancer diagnosis",
      "id": "f308aa75-bf4f-4067-a267-d99009f370ce",
      "llm_source_text_fragment": "Entity index 24",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}